CASE STUDIES
Real Results from Complex Life Science Initiatives
See how MKA Insights helps cell and gene therapy, bioprocessing, medical device and biopharma companies solve strategic challenges and accelerate growth
Commercial Strategy in Action | Entering Markets with Confidence
Highest Impact
CS #10 · COMMERCIAL STRATEGY
Program Management & Business Transformation
Taking Breakthrough Technology From Proof-of-Concept to Commercial Launch Over 2.5 Years
After five years of R&D investment, a leading bioprocessing consumables supplier had proven their capital equipment technology worked. MKA led a 2.5-year program management engagement spanning viability assessment, pricing, VOC research, NPD across 9 products, sourcing, validation, facilities, and financial modeling — concluding with 9 products at validation-ready status and purchase interest from 3 major biopharma customers.
CS #1 · COMMERCIAL STRATEGY
Commercial Viability Assessment & Strategic Pivot
How a 3-Month Assessment Prevented a Multi-Million Dollar Strategic Misstep
After five years of R&D investment, a bioprocessing supplier faced a defining decision: build direct or license through an OEM. MKA researched the landscape, interviewed prospective customers, and built scenarios comparing both paths. The finding that changed everything: this was not a product launch — it was the creation of a new business unit.
CS #2 · COMMERCIAL STRATEGY
Complex Pricing Strategy & Financial Modeling
Building a Pricing Architecture for a Multi-Revenue-Stream Capital Equipment Business
A bioprocessing supplier launching its first capital equipment product couldn’t apply existing pricing expertise to a system with 30+ cost components. MKA built a detailed cost model, established the value-based ceiling above the cost-plus floor, and developed four integrated pricing scenarios — preventing systematic underpricing at launch.
CS #17 · COMMERCIAL STRATEGY
Financial Analysis & Decision Support
Five Financial Models, Five Decisions, One 2.5-Year Engagement
A bioprocessing company needed financial analysis relevant across an entire multi-year program. MKA built five distinct frameworks serving five different decisions — from initial go/no-go through sourcing negotiations — confirming customer willingness to pay substantially above cost-plus pricing.
CS #21 · COMMERCIAL STRATEGY
Global Distribution Strategy
Turning a Chaotic Distributor Network Into a Structured Global Channel Strategy
After being acquired by a large healthcare provider, a bioprocessing company discovered it had no formal contracts, pricing transparency, or commercial leadership across its global distributor network. MKA conducted a forensic analysis of every distributor relationship, segmented partners into strategic tiers, and negotiated region-by-region contracts — replacing handshake deals with standardized terms, global pricing visibility, and a single point of accountability for the channel.
CS #22 · COMMERCIAL STRATEGY
European Market Entry Playbook
Building a European Expansion Playbook From One Successful Sales Hire to a Direct Operations Roadmap
A US-based life sciences tools company had relied on a European distribution partner, but one direct sales hire generated strong enough results to raise a bigger question: where to invest next. MKA built a comprehensive European Market Playbook covering headcount, logistics, banking, legal structure, and tax implications — with built-in flexibility that let the Company navigate Brexit-era uncertainty without losing momentum.
Marketing & Branding | Positioning That Earns Trust
Highest Impact
CS #20 · Marketing
Forensic Content Analysis & Brand Consolidation
500+ Assets, 300+ Presentations, 3 Brand Identities — Consolidated Into One Framework in 12 Weeks
An enterprise software provider had accumulated 500+ marketing assets and 300+ unique sales presentations across five years of M&A activity. None had been consolidated. Three visual brand identities coexisted in materials reaching the same customers. MKA developed a structured forensic review methodology, analyzed every active sales presentation and 220+ high-impact marketing assets, and synthesized the findings into a 252-slide unified framework organized by customer use case rather than product feature. The gold was buried, not missing.
CS #4 · marketing
Brand Development for Capital Equipment
Entering a New Market with a Brand the Market Would Realistically Adopt and Believe
A bioprocessing consumables supplier had spent five years developing breakthrough capital equipment technology — but the company was known exclusively for consumables, not machines. Launching without a deliberate brand strategy meant letting the market draw its own conclusion. MKA led a sub-brand architecture decision, a structured naming process from creative brief through legal clearance, and a three-tier messaging framework — capturing the Halo Effect of existing trust while giving capital equipment its own credible identity.
CS #11 · marketing
Brand Strategy & Market Positioning — Cell & Gene Therapy
Building a Differentiated CGT Brand Position Grounded in Technical Depth, Not Marketing Claims
An established biospecimen and analytics provider entering the Cell & Gene Therapy market had real capabilities — GMP-grade Leukopaks, advanced analytics, a large recallable donor base. What it lacked was positioning built for CGT buyers: technically sophisticated, risk-averse, and evaluating strategic partners rather than transactional suppliers. MKA’s research surfaced three foundational insights, including the donor base as the primary competitive moat, and the right strategic position: CGT Solutions Provider — not Leukopak supplier.
CS #14 · marketing
Messaging Architecture & Framework — CGT Multi-Stakeholder
Organizing a Complex CGT Value Proposition Into a Framework Sales Teams Actually Use
With brand strategy, competitive positioning, and customer personas complete, a CGT market entrant faced the translation challenge: how do you move from strategy documents to messaging sales teams actually use? MKA developed a three-tier messaging hierarchy — Brand Promise for executive conversations, The Offering for technical evaluators, The Proof for scientific and quality audiences — organized around Safety, Specificity, and Analysis.
CS #23 · marketing
Bioprocessing Brand Transformation
Reclaiming 100,000+ Monthly Brand Searches Lost to Corporate Brand Standards After Acquisition
Five years after being acquired by a multi-billion dollar life sciences conglomerate, a bioprocessing business unit was losing 100,000+ monthly brand searches because corporate standards prohibited use of its legacy name — customers were searching for products they couldn’t find. MKA conducted a forensic brand analysis, launched a strategic rebranding campaign at a major industry trade show, and built sustained regional messaging — turning a compliance problem into a strategic asset the CEO and Board recognized as a model for brand integration.
CS #13 · marketing
Brand Strategy & Halo Effect — CGT Repositioning
Leveraging Decades of Brand Equity to Accelerate Credibility in a New Market
An established biospecimen provider entering the Cell & Gene Therapy market faced a brand architecture decision with real costs on both sides. A separate CGT brand would forfeit decades of earned trust; legacy positioning unchanged would make the company look like a transactional supplier chasing a hot market. MKA’s brand equity transferability assessment recommended a Master Brand architecture — capturing the Halo Effect from existing relationships while repositioning toward CGT Solutions Partner.
Product Development | From Concept to Validation-Ready
CS #5 · Product development
NPD & Technical Documentation — 9-Product Portfolio
Advancing 9 Interdependent Products Through Stage-Gate Over 2.5 Years
A bioprocessing consumables supplier developing its first capital equipment platform needed to advance nine products simultaneously through a formal stage-gate process — one integrated equipment system plus eight associated consumables, with interdependencies running in every direction. MKA assumed dedicated program management leadership across the entire portfolio: facilitating monthly gate reviews, coordinating a 15-person cross-functional team, defining and overseeing 400+ pages of DHF documentation, and establishing the validation strategy framework that gave internal quality teams and external specialists a coherent mandate.
CS #6 · PRODUCT DEVELOPMENT
Product Design Optimization & SKU Rationalization
30–40% SKU Reduction Through Design Optimization Before Manufacturing Commitments Were Made
As product specifications were finalized for a new capital equipment system, an operational reality emerged: the architecture as designed would require substantially more storage space, kitting complexity, and inventory overhead than anticipated. MKA conducted a systematic audit to distinguish complexity customers genuinely needed from complexity inherited from development iteration history, driving a 30–40% reduction in SKU count through component standardization and modular architecture design.
CS #8 · PRODUCT DEVELOPMENT
Validation Strategy & Manufacturing — IQ/OQ/PQ Framework
Establishing a Coherent Validation Framework Across Multi-Site Capital Equipment Manufacturing
Before engaging IQ/OQ/PQ validation specialists, a bioprocessing company entering equipment manufacturing needed the strategic framework that would give those specialists a coherent mandate. MKA established the master validation strategy — scope, site responsibilities, critical process parameters, acceptance criteria philosophy, and consolidated reporting requirements — coordinating across multiple contract manufacturers with different quality systems.
Sales Excellence | Turning Teams Around
Highest Impact
CS #19 · sales excellence
Business Transformation & Organizational Turnaround — Post-M&A
$10M In, $100K Out: Restoring Commercial Effectiveness After Five Years of M&A Fragmentation
A 50-person commercial organization representing roughly $10M in annual investment had generated less than $100K in new bookings. Leadership’s instinct was to look at seller skill. MKA’s diagnosis found something different: five years of accumulated M&A activity had fragmented positioning, messaging, and go-to-market ownership across the organization — sellers weren’t underperforming, they were working without a unified story. MKA interviewed 50+ sellers directly, then delivered a consolidated positioning framework live at the annual sales meeting. Leadership described the response as relief.
CS #24 · sales excellence
Heat Mapping Sales Territory
Data-Driven Sales Territory Alignment & Design, Replacing Territory Guesswork with Performance Analytics
A clinical diagnostics lab offering a specialized prostate cancer screening test had sales territories based on assumptions — geographic convenience and historical precedent, with no data behind them. MKA built a market demand heat map across urologists, practices, and academic medical centers, then overlaid actual performance data to expose where sales resources were stretched too thin and where high-potential accounts were going uncovered. The redesign gave the Company data-driven territory boundaries, realistic rep-to-account ratios, and performance benchmarks reps could actually be held to fairly.
Operations Excellence | Solving Real Constraints
Highest Impact
CS #16 · operations
Facilities Needs Assessment & Manufacturing Strategy
From 4,200 to 925 Square Feet: How Packaging Strategy, Not Facility Investment, Solved a Space Problem
A bioprocessing company scaling capital equipment manufacturing through CMO partnerships faced a question that looked simple but wasn’t: how much space do we actually need? An initial estimate of 4,200 sq ft of pallet storage turned out to be an output of supplier packaging decisions, not a fixed constraint. MKA’s redesign of incoming packaging reduced storage requirements by 77% — without changing a single product specification — while also uncovering a strategic reframe: the CMO’s real value was space, not expertise, pointing toward bringing manufacturing in-house as volumes matured.
CS #7 · operations
Strategic Sourcing & Partnerships — Capital Equipment
Building Strategic Manufacturing Partnerships for a First-Time Capital Equipment Entrant
MKA led 14–18 months of dedicated sourcing program management for a bioprocessing supplier entering capital equipment manufacturing — segmenting 30+ components by strategic value, qualifying manufacturing partners, and structuring agreements covering pricing, tooling investment, and capacity commitments. The resulting partnerships became a supply chain competitive advantage rather than a launch-day dependency.
CS #9 · OPERATIONS
Facilities Planning & Manufacturing Infrastructure Design
Designing Manufacturing Infrastructure From the Ground Up for a First Capital Equipment Launch
MKA conducted a comprehensive facilities assessment mapping complete production requirements — storage, workflow, cold chain, kitting, and QC — modeled across launch volumes and multi-year growth scenarios, delivered in two months ahead of the client’s manufacturing buildout decisions.
Market Intelligence | Research that Changes Decisions
Highest Impact
CS #15 · market intelligence
Market Research & Technical Analysis — CGT Regulatory Landscape
The Technical Research That Made Everything Else in the CGT Engagement Possible
Before brand positioning, personas, or messaging could be built for a CGT market entry, someone had to understand what regulators and quality teams actually required. MKA reviewed 10+ FDA guidance documents and mapped critical quality attributes as an interconnected system rather than isolated checkboxes. The analysis produced the Purity Paradox — the insight that Identity cannot be reliably confirmed without first characterizing Purity — the foundational intelligence layer underneath the brand and messaging work that followed.
CS #3 · market intelligence
Voice of Customer & Beta Testing
Replacing Engineering Assumptions with Buyer Evidence Before a Capital Equipment Launch
What engineers believed drove a capital equipment purchase decision and what actually drove it were not the same thing. MKA ran 20+ stakeholder interviews and a three-site beta program ahead of launch, surfacing real pain points, pricing logic, and the internal stakeholder dynamics that shaped how the launch strategy was ultimately built.
CS #12 · market intelligence
Customer Persona Development — B2B CGT Buying Dynamics
Mapping Who Actually Makes CGT Purchasing Decisions — and Who Can Kill Them
Cell & Gene Therapy purchasing involves five distinct stakeholder types with counterintuitive influence patterns. MKA’s 20+ direct interviews found that scientists hold de facto veto authority at the earliest stage of the buying process — well before commercial or procurement conversations even begin.
CS #18 · market intelligence
Materials Science Research & Competitive Intelligence
14 Competitor Films Analyzed: Building the Technical Foundation for Strategic Sourcing Decisions
A medical device company sourced film — its single most critical raw material — on relationship, not analysis. MKA systematically evaluated 14 competitor films and identified supplier vulnerabilities before customers discovered them independently, establishing a near/mid/long-term film strategy grounded in materials science rather than vendor relationships.
CS #25 · market intelligence
Market Intelligence for EHR Market
Decoding an Opaque Market Using Creative Research and FOIA Requests
A global medical device manufacturer wanted to explore the Electronic Health Records market but had no industry familiarity and no visibility into the privately-owned market leader — with pricing data locked behind proprietary contracts that couldn’t ethically be extracted through interviews alone. MKA combined structured multi-source interviews with an unconventional research technique: locating executed public-sector contracts through legitimate disclosure channels to reverse-engineer pricing models most researchers assume are unobtainable, delivering platform, pricing, and partnership intelligence without compromising any confidentiality agreement.
CS #26 · market intelligence
Clinical Pipeline & Commercial Intelligence
Turning Clinical Pipeline Data Into Commercial Intelligence for Faster Investment Decisions
A market-leading bioprocessing company had rich CRM data and access to third-party biologics pipeline intelligence, but no way to connect them into a coherent view of where to invest. MKA built integrated reporting that mapped customer accounts against clinical pipeline programs by molecule type, therapeutic area, and manufacturing modality — turning intuition-based resource allocation into data-informed decisions and giving account teams early warning of shifts before competitors caught on.
Ready to discuss your challenges?
Whether you’re exploring a strategic initiative or need hands-on execution support, we’re here to help.